MY147226A - Method of inhibiting c-kit kinase - Google Patents

Method of inhibiting c-kit kinase

Info

Publication number
MY147226A
MY147226A MYPI20084185A MYPI20084185A MY147226A MY 147226 A MY147226 A MY 147226A MY PI20084185 A MYPI20084185 A MY PI20084185A MY PI20084185 A MYPI20084185 A MY PI20084185A MY 147226 A MY147226 A MY 147226A
Authority
MY
Malaysia
Prior art keywords
kit
inhibiting
subject
present
kit kinase
Prior art date
Application number
MYPI20084185A
Other languages
English (en)
Inventor
Carl R Illig
Shelley K Ballentine
Chen Jingsheng
Saneth K Meegalla
Mark J Wall
Kenneth J Wilson
Rudolph M Jonathan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MY147226A publication Critical patent/MY147226A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20084185A 2006-04-20 2008-10-20 Method of inhibiting c-kit kinase MY147226A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79347106P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
MY147226A true MY147226A (en) 2012-11-14

Family

ID=38625740

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20084185A MY147226A (en) 2006-04-20 2008-10-20 Method of inhibiting c-kit kinase

Country Status (21)

Country Link
EP (2) EP2397138B1 (enExample)
JP (1) JP5595727B2 (enExample)
KR (1) KR101448052B1 (enExample)
CN (2) CN101610768B (enExample)
AU (1) AU2007240400B2 (enExample)
BR (1) BRPI0710542B8 (enExample)
CA (1) CA2649755C (enExample)
CO (1) CO6382175A2 (enExample)
CR (1) CR10450A (enExample)
EA (1) EA016611B1 (enExample)
EC (1) ECSP088842A (enExample)
ES (2) ES2389678T3 (enExample)
GT (1) GT200800225A (enExample)
IL (1) IL194846A (enExample)
MX (1) MX2008013528A (enExample)
MY (1) MY147226A (enExample)
NO (1) NO342001B1 (enExample)
NZ (1) NZ572200A (enExample)
SG (1) SG171592A1 (enExample)
WO (1) WO2007124369A2 (enExample)
ZA (1) ZA200809874B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012288900B2 (en) 2011-07-27 2016-10-06 Ab Science Selective protein kinase inhibitors
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
TWI693221B (zh) 2015-01-15 2020-05-11 瑞士商愛杜西亞製藥有限公司 作為ｃｘｃｒ３受體調節劑之羥烷基六氫吡衍生物
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
DE60316810T2 (de) * 2002-08-02 2008-07-17 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
PL1684750T3 (pl) * 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
CA2554925A1 (en) * 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
ES2611604T3 (es) * 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP1951234A2 (en) * 2005-10-18 2008-08-06 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
MX2008013533A (es) * 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
EP2016070B1 (en) * 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
EP2016057A1 (en) * 2006-04-20 2009-01-21 Janssen Pharmaceutica N.V. C-fms kinase inhibitors

Also Published As

Publication number Publication date
SG171592A1 (en) 2011-06-29
IL194846A0 (en) 2009-08-03
ZA200809874B (en) 2010-02-24
NO20084892L (no) 2009-01-06
EA200870454A1 (ru) 2009-04-28
EP2015748B1 (en) 2012-07-04
IL194846A (en) 2015-07-30
MX2008013528A (es) 2008-10-29
BRPI0710542A2 (pt) 2012-06-05
EP2397138B1 (en) 2013-12-11
CR10450A (es) 2009-02-23
CO6382175A2 (es) 2012-02-15
ES2389678T3 (es) 2012-10-30
CA2649755C (en) 2014-12-02
CN102670605A (zh) 2012-09-19
CN101610768B (zh) 2012-03-21
CN102670605B (zh) 2015-07-29
EP2397138A1 (en) 2011-12-21
KR20080111545A (ko) 2008-12-23
GT200800225A (es) 2009-05-15
BRPI0710542B1 (pt) 2021-01-12
CN101610768A (zh) 2009-12-23
JP5595727B2 (ja) 2014-09-24
AU2007240400B2 (en) 2013-08-22
CA2649755A1 (en) 2007-11-01
ECSP088842A (es) 2008-11-27
WO2007124369A3 (en) 2008-03-06
NZ572200A (en) 2011-09-30
JP2009534418A (ja) 2009-09-24
AU2007240400A1 (en) 2007-11-01
NO342001B1 (no) 2018-03-12
EP2015748A2 (en) 2009-01-21
HK1124766A1 (en) 2009-07-24
WO2007124369A2 (en) 2007-11-01
KR101448052B1 (ko) 2014-10-07
BRPI0710542B8 (pt) 2021-05-25
EA016611B1 (ru) 2012-06-29
ES2458291T3 (es) 2014-04-30

Similar Documents

Publication Publication Date Title
WO2007048088A3 (en) Method of inhibiting flt3 kinase
SG171592A1 (en) Method of inhibiting c-kit kinase
TNSN08478A1 (en) Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009009786A (es) Inhibidores de la via de hedgehog.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
MX2009013218A (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus.
TW200801007A (en) Triazolopyridazines as kinase modulators
MX2009006690A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
UA101602C2 (ru) Производные бензамидов как антагонисты брадикининовых рецепторов
IL192949A0 (en) Kinase inhibitors and methods of use thereof
MX2007015741A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.